S. Rouan
Director/Board Member bij VIKING THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
S.
Kathryn Rouan is an Independent Director at Viking Therapeutics, Inc. and a Non-Executive Director at Code Biotherapeutics, Inc. She was the Chairman at Navidea Biopharmaceuticals, Inc. from 2018 to 2021.
Prior to that, she was the Senior VP, Head-Research & Development at Stiefel Laboratories, Inc. from 2013 to 2016, and the SVP, Head-Projects, Clinical Platforms & Sciences at GlaxoSmithKline LLC from 2016 to 2018.
She was also a Vice President at GlaxoSmithKline LLC from 2003 to 2013.
Rouan holds a doctorate degree from the University of Rhode Island and a graduate degree from the University of London.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van S. Rouan
| Bedrijven | Functie | Begin |
|---|---|---|
| VIKING THERAPEUTICS, INC. | Director/Board Member | 01-07-2019 |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Director/Board Member | - |
Eerdere bekende functies van S. Rouan
| Bedrijven | Functie | Einde |
|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Chairman | 14-09-2021 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01-12-2018 |
Stiefel Laboratories, Inc.
 Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Chief Tech/Sci/R&D Officer | 01-05-2016 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01-12-2013 |
Opleiding van S. Rouan
| University of Rhode Island | Doctorate Degree |
| University of London | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| VIKING THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Stiefel Laboratories, Inc.
Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
